Last updated: May 9, 2026
Relacorilant: Clinical Trials Update, Market Analysis, and 2025 to 2035 Projection
What is relacorilant and where is it in clinical development?
Relacorilant (also styled as Relacorilant/RelacoriLant in filings) is an investigational oral antagonist of the glucocorticoid receptor (GR) with development intent spanning endocrine-related and oncology-adjacent settings where glucocorticoid signaling drives resistance and/or symptom biology.
Across public development tracking, relacorilant’s clinical program is led by Phase 2 studies, with Phase 1-to-2 translational readouts informing dosing and biomarker strategies. Trial execution cadence and enrollment updates are reflected in ClinicalTrials.gov postings and company disclosures tied to regulatory conferences and quarterly reporting.
Primary public development channels
- ClinicalTrials.gov: protocol listings, status changes, primary completion and results records where available.
- Regulatory conference materials: poster and abstract releases that often drive near-term interpretation even when full datasets are pending on clinical trial registries.
- Corporate updates: investor presentations and press releases that summarize enrollment pace and next-step plans.
Clinical status snapshot (public record)
| Indication (publicly listed) | Trial phase (public) | Register source type | Latest observable event type* |
|---|---:|---|---|
| Endocrine/oncology-associated GR-driven biology | Phase 1/2 or Phase 2 | ClinicalTrials.gov + conference abstracts | Enrollment updates; protocol amendments; biomarker and efficacy readouts where posted |
| Other mechanistically aligned cohorts | Phase 2 (or multi-arm) | ClinicalTrials.gov | Status progression, primary completion timelines, results posting (when available) |
*“Latest observable event type” reflects the typical pattern in ClinicalTrials.gov updates, where the last-posted date may change due to administrative updates or milestone changes.
Which clinical readouts and endpoints matter for valuation now?
For GR antagonists, trial success depends less on raw symptom reduction alone and more on demonstrating:
- Pharmacodynamic engagement (GR pathway modulation in tissue or surrogate biomarkers).
- Durability of response in recurrent or resistant populations.
- Combination logic where GR blockade can restore chemo- or endocrine-sensitivity.
For relacorilant specifically, business-critical signals are those that tighten:
- dose selection (exposure-response curves),
- biomarker-defined activity (marker positivity thresholds),
- and clinically meaningful endpoints in the target population described in the protocol.
Decision gates that investors price in
- Phase 2 endpoint achievement: statistically meaningful signal with manageable safety.
- Biomarker enrichment: response concentrates in pre-specified biomarker-positive cohorts.
- Regulatory pathway clarity: whether evidence supports conditional approval strategy or label narrowing.
Where do relacorilant trials stand by geography and recruitment pace?
Relacorilant development is conducted through multi-site programs with a mix of US and international sites typical for Phase 2 investigational GR antagonists. Public trial records show:
- ongoing recruitment and active status in several protocols,
- iterative updates to recruitment status and completion dates as enrollment evolves,
- protocol amendments that can adjust dosing, stratification, or endpoint timing.
From a market-shaping standpoint, the main observable constraints are:
- recruitment timelines (how fast the sponsor reaches the target sample size),
- endpoint timing (how soon primary readouts mature after last patient in),
- cohort execution (single-cohort vs multi-cohort designs).
What does the safety and tolerability profile imply for market potential?
For GR antagonists, safety expectations usually anchor on:
- endocrine axis effects (recovery of endogenous cortisol dynamics),
- metabolic and psychiatric adverse events,
- GI and general tolerability in chronic dosing.
In practice, payers and formularies price relacorilant on whether the safety burden is:
- lower than existing competitors or standard-of-care add-ons,
- predictable and manageable with monitoring,
- compatible with long treatment durations.
Commercially relevant safety questions
- Does relacorilant require intensive monitoring that increases real-world cost?
- Does it create discontinuation risk that caps achievable adherence?
- Does it reduce the need for high-dose steroids or other supportive medication?
Who are relacorilant’s competitive comparators and what do they set as benchmarks?
GR antagonism sits in a competitive landscape shaped by:
- existing hormone receptor modulation therapies,
- glucocorticoid-sparing strategies in inflammatory and oncology-adjacent care,
- and emerging steroid receptor competitors depending on indication.
Benchmarks typically include:
- effect size measured against historical controls,
- safety profile in chronic dosing,
- and the plausibility of combination regimens as standard practice.
A relacorilant label expansion path is most viable when trial endpoints show incremental benefit over a realistic baseline regimen and when mechanism translates into measurable clinical activity.
Relacorilant market analysis: addressable population, reimbursement logic, and uptake assumptions
What is the near-term commercial opportunity by indication?
Because relacorilant’s most relevant label-claim depends on which Phase 2 readout becomes definitive, the market model should be structured by indication “launch package” rather than a single global TAM.
A commercial model for relacorilant typically uses three layers:
- Diagnosed population in the target geography mix.
- Eligible fraction based on stage and biomarker criteria.
- Treatment adoption rate based on mechanism benefit, safety, and line-of-therapy positioning.
Market modeling framework
| Model component | Practical input | Commercial impact |
|---|---|---|
| Diagnosed population | Incidence and prevalence by disease | Sets ceiling TAM |
| Eligibility | Biomarker and line-of-therapy criteria | Drives SAM |
| Uptake curve | Adoption speed from guideline penetration and physician behavior | Determines revenue timing |
What pricing and reimbursement structure is most likely used?
For oral investigational therapies in oncology-adjacent and endocrine-linked indications, pricing commonly follows:
- premium pricing relative to supportive-only regimens,
- reimbursement conditioned on biomarker or line-of-therapy placement,
- and value-based adjustments after Phase 3 maturity.
A realistic projection framework uses:
- list price assumptions aligned with branded oral oncology therapies,
- net price after rebates and discounts,
- and early reimbursement restrictions that can evolve post pivotal data.
How does the competitive position translate into market share?
Market share depends on:
- whether relacorilant is positioned as a monotherapy vs add-on,
- whether it replaces supportive steroids,
- and whether it establishes a new standard line-of-therapy.
In practice, uptake accelerates when:
- Phase 2 data shows clear separation on primary endpoints,
- there is a biomarker-defined responsive subgroup,
- and safety allows outpatient chronic administration.
2025 to 2035 revenue projection: base, bull, and bear cases
What revenue model drives the projection?
The projection uses a launch-year adoption ramp with a plateau governed by:
- the maximum eligible population treated,
- competitive dynamics from existing therapies,
- and label breadth (biomarker gating vs broad use).
Key projection mechanics
- Launch year: anchored to the earliest plausible regulatory submission window implied by Phase 2 progress timelines and typical oncology/endocrine drug regulatory pacing.
- Adoption curve: starts slow due to payer and guideline inertia, then accelerates after confirmatory data or strong Phase 2-to-3 continuity.
- Attrition: assumes discontinuation due to safety and switching due to competitor advantage.
Base-case revenue projection (2025 to 2035)
| Year |
Global revenue (base case) |
Notes tied to adoption ramp |
| 2025 |
0 |
Pre-approval period in base path |
| 2026 |
0 to low |
If early submission-to-approval occurs late in year |
| 2027 |
ramp begins |
initial uptake in treated eligible population |
| 2028 |
accelerating |
formulary inclusion and physician confidence increase |
| 2029 |
growth to plateau |
label stabilization and combination adoption |
| 2030 to 2035 |
mature plateau with mild growth/decline |
depends on durability and competitive entrants |
Bull-case revenue projection
Bull case assumes:
- clearer clinical differentiation on Phase 2 primary endpoint(s),
- biomarker enrichment increases responder share,
- and combination uptake makes relacorilant a standard backbone rather than a niche add-on.
| Year |
Global revenue (bull case) |
| 2027 |
higher ramp |
| 2028 to 2032 |
sustained growth |
| 2033 to 2035 |
plateau at a higher ceiling or modest decline |
Bear-case revenue projection
Bear case assumes:
- endpoint signal is mixed or restricted to small biomarker subgroups,
- safety or tolerability limits chronic use,
- or competitor classes compress pricing and adoption.
| Year | Global revenue (bear case) |
|---:|
| 2027 | limited uptake |
| 2028 to 2031 | flattening |
| 2032 to 2035 | low growth with competitive pressure |
Important for readers using the projection: the numeric values above are structurally dependent on which indication wins the label and the launch year. Without an explicit finalized indication set and pricing/net reimbursement inputs, the model is best used as an adoption-based scenario map rather than a single point estimate.
Key near-term catalysts that can move the stock or pipeline value
What events should trigger rapid repricing?
- Phase 2 primary endpoint readout with statistically credible efficacy and interpretable biomarker response.
- Dose and exposure-response clarity that reduces regulatory uncertainty.
- Safety updates indicating low discontinuation and manageable endocrine effects.
- Design updates for Phase 3: biomarker gating, cohort sizes, and endpoint selection.
- Regulatory interaction signals: alignment on Phase 3 path and potential expedited strategies where relevant.
Key Takeaways
- Relacorilant is a GR antagonist with Phase 2-led momentum, where value hinges on biomarker engagement and clean Phase 2 clinical differentiation rather than class-level expectations.
- The market opportunity depends on whether relacorilant launches in a broad eligible population or a narrow biomarker-selected niche, and whether it becomes a backbone therapy via combination adoption.
- A 2025 to 2035 revenue view is best expressed as scenario-based adoption: base case assumes measured uptake, bull case assumes responder enrichment and guideline penetration, bear case assumes label narrowing and competitive compression.
FAQs
-
What clinical endpoint will most influence relacorilant’s valuation?
The pivotal driver is performance on the Phase 2 primary endpoint paired with demonstrable pharmacodynamic biomarker engagement.
-
Does relacorilant likely face safety monitoring barriers?
GR antagonists commonly require endocrine-axis monitoring; commercialization depends on whether adverse events remain manageable with outpatient workflows.
-
How does biomarker gating change relacorilant’s market size?
Biomarker gating can shrink SAM but can increase responder conversion, improving payer willingness and long-term profitability per treated patient.
-
Is relacorilant more likely to sell as monotherapy or combination therapy?
Mechanism-driven GR antagonists typically outperform when placed as add-on or backbone therapy where they restore treatment sensitivity.
-
What event has the highest probability of accelerating uptake?
A clear Phase 2-to-Phase 3 continuity package with a regulatory-aligned endpoint plan and safety stability is the fastest path to formulary adoption.
References
[1] ClinicalTrials.gov. Study records for relacorilant (relacorilant/related identifiers). https://clinicaltrials.gov/
[2] PubMed. Publications and conference-indexed abstracts mentioning relacorilant. https://pubmed.ncbi.nlm.nih.gov/
[3] Company investor materials and regulatory conference disclosures referencing relacorilant (accessed via company IR pages).
